There are 2867 resources available
450O - Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition
Presenter: Anthony Tolcher
Session: Proffered Paper session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies
Resources:
Webcast
Discussion
Presenter: All Speakers
Session: Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC
Resources:
Webcast
Invited Discussant 1735O and LBA74
Presenter: Rana McKay
Session: Proffered Paper session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
Invited Discussant LBA14 and 134O
Presenter: Peter Dubsky
Session: Proffered Paper session: Breast cancer, early stage
Resources:
Slides
Webcast
Invited Discussant 1485O and 1484O
Presenter: Jakob Kather
Session: Proffered Paper session: Sarcoma
Resources:
Slides
Webcast
CN14 - Cancer prevention awareness among Croatian AYA population
Presenter: Nikolina Dodlek
Session: Health promotion, prevention, and screening
Resources:
Abstract
LBA33 - 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study
Presenter: Jean Bourhis
Session: Mini Oral session: Head & neck cancer
Resources:
Abstract
Slides
Webcast
454O - A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)
Presenter: Christina Guo
Session: Proffered Paper session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Breast cancer, early stage
Resources:
Webcast